Status:
COMPLETED
Effectiveness and Safety of Omalizumab in Children With Allergic Asthma.
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Allergic Asthma
Eligibility:
All Genders
6-11 years
Brief Summary
The study was the non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treat...
Detailed Description
This non-interventional, retrospective study aimed to assess the effectiveness and safety of omalizumab in children with allergic asthma in China, and described patient profiles and treatment patterns...
Eligibility Criteria
Inclusion
- Aged between 6 -\<12 years
- Diagnosed with allergic asthma and could be treated using omalizumab. Comorbidities included allergic rhinitis, atopic dermatitis, nasal polyp, chronic urticaria, and food allergy
- Received omalizumab during the identification period
- Had at least one documented follow-up data after omalizumab treatment
- Provided informed consent if required by ethics committee (EC) of hospital
Exclusion
- Current participation in a clinical trial of any investigational treatment
Key Trial Info
Start Date :
February 25 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 28 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT05424523
Start Date
February 25 2021
End Date
June 28 2021
Last Update
July 5 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
East Hanover, New Jersey, United States, 07936-1080